Skip to content

RxSight, Inc. RXST Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Schering-Plough logo
Schering-PloughSGP

Other financials

Income statement

See full
Revenue$30.9M-18.5%
Gross profit$23.5M-17.1%
Operating income-$17.8M-67.0%
Net income-$15.9M-93.9%
EPS (diluted)-$0.38-90.0%

Balance sheet

See full
Cash & equivalents$17.6M-37.2%
Total debt$10.8M-10.1%
Total equity$267.3M-4.3%
Total assets$304.0M-2.9%

Cash flow

See full
Operating cash flow-$10.9M-23.3%
CapEx$759.0K+32.0%
Free cash flow-$11.7M-23.8%

Valuation

See full
Market cap$232.23M-56.8%
Enterprise value$225.49M-55.7%
P/S1.8×-1.8×

Profitability

See full
Gross margin77%+5.1pp
Operating margin-43.4%+128pp
Net margin-36.6%-867pp
FCF margin-16.9%+4.9pp

Returns & leverage

See full
Return on equity-17.1%+12.6pp
Debt / equity0.0×
Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: RxSight, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RxSight, Inc.'s payments of stock issuance costs?
RxSight, Inc. (RXST) reported payments of stock issuance costs of $0 in Q4 2025.
What is the long-term trend for RxSight, Inc.'s payments of stock issuance costs?
Over 2 years (2022 to 2024), RxSight, Inc.'s payments of stock issuance costs has grown at a 14.4% compound annual growth rate (CAGR), from $587K to $768K.
What does payments of stock issuance costs mean?
This represents the direct cash costs incurred in connection with the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. These costs are typically deducted from the gross proceeds of the offering. Tracking these expenses helps investors understand the efficiency of the company's capital-raising activities.